Daniel J. Jackson
University of Wisconsin School of Medicine and Public Health; Division of Allergy & Immunology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel J. Jackson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05347771 · Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and AdolescentsNational Institute of Allergy and Infectious Diseases (NIAID) · active not recruiting · Asthma · study chair
- N/ANCT05272241 · Registry of Asthma Characterization and Recruitment 3 (RACR3)National Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Asthma · study chair
- Ph2NCT03292588 · A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban ChildrenNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Asthma
- N/ANCT02502890 · Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based TherapyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Asthma
- N/ANCT00204841 · Childhood Origins of Asthma (COAST)University of Wisconsin, Madison · completed · Asthma, Allergy
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Childhood Asthma in Urban Settings Clinical Research Network - Leadership CenterUM1AI160040 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2021 to 2026 · $6,019,232 awarded in 2026Same name and institution; not confirmed by an ID
- Wisconsin Allergy Research Training (WiscART) ProgramT32AI007635 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2025 to 2026 · $311,965 awarded in 2026Same name and institution; not confirmed by an ID
- Human epidemiology and response to SARS-CoV-2 (HEROS)UM1AI114271 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2019 to 2021 · $403,137 awarded in 2021Grant number is on one of their registry trials
- Rhinovirus Infections and Asthma in Children and AdolescentsP01HL070831 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2016 to 2017 · $2,388,928 awarded in 2017Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.N Engl J Med · 2010328 citationsRCR 9.9
- Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations.J Allergy Clin Immunol · 2014226 citationsRCR 7.2
- Individualized therapy for persistent asthma in young children.J Allergy Clin Immunol · 2016210 citationsRCR 8.9
- 202 citationsRCR 7.6
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med · 2024197 citationsRCR 36.5
- 167 citationsRCR 5.4
- 144 citationsRCR 12.2
- 144 citationsRCR 26.8
- Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.N Engl J Med · 2024140 citationsRCR 23.5
- 105 citationsRCR 5.1